$1.305
+0.333 (+25.48%)收盤時
DWTX 資訊
DWTX 事件
Selling Stockholders Plan to Sell Up to 4.1M Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 4.1M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Dogwood Therapeutics Secures $5M Investment
Dogwood Therapeutics announced that the company has entered into a securities subscription agreement for a $5M investment from the company's largest shareholder, a subsidiary of CK Life Sciences. The investment comes as Dogwood continues to advance its ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain trial toward topline data readout in November 2026. Proceeds from this investment will enable the advancement of Phase 3 preparatory activities and extend operational runway through March 2027. Pursuant to the terms of the Subscription Agreement, Dogwood will issue an aggregate of 4,098,360 shares of common stock at a price of $1.22 per share. The private placement is being priced at-the-market under the rules of The Nasdaq Stock Market. No warrants or other derivative securities are included in the transaction. The private placement is expected to close on or prior to October 29. The company currently expects to use the net proceeds from the private placement to fund Phase 3 preparatory activities for Halneuron and for working capital and general corporate purposes.
Dogwood Enrolls First 200 Patients in HAL-CINP Phase 2b Trial
Dogwood announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.
Dogwood Therapeutics Commences Halneuron Pain Study
Dogwood Therapeutics announced commencement of a new Halneuron chemotherapy induced neuropathic pain phase 2b extension study. "Neuropathic pain is a difficult to treat chronic condition, as evidenced by the five-year mean duration of symptoms for the patients enrolling in our current Halneuron CINP Phase 2b trial," said R. Michael Gendreau, chief medical officer of Dogwood. "This new 12-week long term extension will generate important additional data on how best to optimize Halneuron maintenance treatment for our planned Phase 3 program and potential commercialization".
Dogwood Partners with PRIDCor for $100M Development Agreement
Dogwood announced a global development and commercialization partnership with PRIDCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood's anti-viral candidates, IMC-1 and IMC-2. The agreement includes potential payments of up to $100M to Dogwood and its current and former shareholders. Dogwood Therapeutics previously announced its intention to explore partnership opportunities to advance its combination antiviral drug candidates and shift its primary focus to advancing its NaV 1.7 inhibitor, Halneuron, to treat both chronic and acute pain conditions. Dogwood subsequentially in-licensed SP16, administered via intravenous formulation, as a complement to its lead asset Halneuron. Consistent with its prior announcement, Dogwood has entered into an agreement with PRIDCor pursuant to which PRIDCor will be fully responsible for financing and executing future development, commercialization and intellectual property maintenance for both IMC-1 and IMC-2. In exchange, Dogwood is entitled to a tiered royalty on net sales of up to 15% upon commercialization of IMC-1 or IMC-2. Further, Dogwood is entitled to 9% of all future capital raised by PRIDCor to advance IMC-1 or IMC-2, as well as future PRIDCor partnership-related development and regulatory payments associated with IMC-1 or IMC-2. Potential payments to Dogwood under the development partnership are capped at $100M.
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。